TD Cowen analyst Joseph Thome maintained a Buy rating on United Therapeutics today and set a price target of $400.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Thome has given his Buy rating due to a combination of factors including United Therapeutics’ solid performance and growth potential. The company’s Q2 revenues were nearly in line with expectations, driven by the strong performance of the treprostinil franchise. Despite a slight miss for Tyvaso, management expressed confidence in the product’s long-term growth prospects, supported by record levels of referrals, starts, and patient shipments.
Furthermore, United Therapeutics’ management remains optimistic about the company’s ability to sustain revenue growth in the near term, particularly in the PAH and PH-ILD markets. The announcement of a $1 billion share repurchase authorization reflects management’s confidence in upcoming catalysts, such as the anticipated Phase III TETON-2 results. This strategic move, along with the company’s growth potential and management’s proactive approach, underpins Thome’s Buy rating.
According to TipRanks, Thome is an analyst with an average return of -4.5% and a 38.18% success rate. Thome covers the Healthcare sector, focusing on stocks such as Alkermes, Jazz Pharmaceuticals, and United Therapeutics.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $343.00 price target.